Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets (2021 - 2026)

Centessa Pharmaceuticals has reported Non-Current Assets over the past 5 years, most recently at $319.6 million for Q4 2025.

  • Quarterly Non-Current Assets rose 691.35% to $319.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $832.1 million through Dec 2025, up 393.04% year-over-year, with the annual reading at $319.6 million for FY2025, 691.35% up from the prior year.
  • Non-Current Assets was $319.6 million for Q4 2025 at Centessa Pharmaceuticals, up from $140.6 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $319.6 million in Q4 2025 and troughed at $861000.0 in Q4 2021.
  • The 5-year median for Non-Current Assets is $42.5 million (2023), against an average of $68.5 million.
  • Year-over-year, Non-Current Assets skyrocketed 2637.15% in 2023 and then dropped 10.55% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $861000.0 in 2021, then soared by 661.9% to $6.6 million in 2022, then soared by 588.32% to $45.2 million in 2023, then fell by 10.55% to $40.4 million in 2024, then skyrocketed by 691.35% to $319.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Non-Current Assets are $319.6 million (Q4 2025), $140.6 million (Q3 2025), and $191.8 million (Q2 2025).